Hansoh Pharmaceutical

Hansoh Pharmaceutical's reported carbon emissions

Hansoh Pharmaceutical, a company within the Pharmaceutical Preparation Manufacturing industry based in China (CN), is actively working to reduce its environmental impact. **Carbon Emissions Data:** In 2024, Hansoh Pharmaceutical reported total global greenhouse gas emissions of approximately 70,686,750 kg CO2e, encompassing Scope 1, 2, and 3. This breaks down into: * **Scope 1:** Approximately 13,163,250 kg CO2e. * **Scope 2:** Approximately 95,364,120 kg CO2e (market-based). * **Scope 3:** Approximately 55,724,800 kg CO2e, with purchased goods and services accounting for approximately 11,602,470 kg CO2e and capital goods for about 2,238,550 kg CO2e. For 2023, total global emissions were approximately 77,766,960 kg CO2e. * **Scope 1:** Approximately 10,546,850 kg CO2e. * **Scope 2:** Approximately 81,565,210 kg CO2e. * **Scope 3:** With purchased goods and services at approximately 11,854,930 kg CO2e and capital goods at about 1,631,040 kg CO2e. In 2022, total global emissions were approximately 86,744,570 kg CO2e. * **Scope 1:** Approximately 9,024,600 kg CO2e. * **Scope 2:** Approximately 77,719,970 kg CO2e. * **Scope 3:** With purchased goods and services at approximately 1,445,300 kg CO2e and capital goods at about 28,230 kg CO2e. For 2021, the company reported Scope 1 and 2 emissions totalling approximately 122,328,000 kg CO2e, with Scope 1 emissions at approximately 6,256,000 kg CO2e and Scope 2 emissions at approximately 116,072,000 kg CO2e. Scope 3 data for this year is not fully disclosed. In 2020, total emissions were approximately 104,650,000 kg CO2e, comprising Scope 1 at about 4,423,480 kg CO2e and Scope 2 at approximately 100,226,420 kg CO2e. Scope 3 data for this year is not fully disclosed. **Climate Commitments and Reduction Targets:** Hansoh Pharmaceutical has set ambitious targets to reduce its environmental footprint. A key commitment is to reduce greenhouse gas emissions per unit of revenue from Scope 1 and Scope 2 by 40% by 2030, using 2021 as the base year. This intensity reduction target applies to all scopes. Furthermore, the company aims to decrease comprehensive energy consumption per unit of revenue by 20% by 2030, also using 2021 as the base year. The company is part of Hansoh Pharmaceutical Group Company Limited, and its emissions data is cascaded from this parent organisation. The group has previously implemented energy-saving initiatives, such as over 10 renovation projects in 2020, which aimed to reduce resource and energy consumption, alongside greenhouse gas emissions.